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Abstract 
Cardiac fibroblasts (CF) play a central role in the repair and remodeling of the heart 
following injury and are important regulators of inflammation and extracellular matrix 
(ECM) turnover. ECM-regulatory matricellular proteins are synthesized by several 
myocardial cell types including CF. We investigated the effects of pro-inflammatory 
cytokines on matricellular protein expression in cultured human CF. cDNA array analysis of 
matricellular proteins revealed that interleukin-1 (IL-1, 10 ng/ml, 6 h) down-regulated 
connective tissue growth factor (CTGF/CCN2) mRNA by 80% and up-regulated tenascin-C 
(TNC) mRNA levels by 10-fold in human CF, without affecting expression of 
thrombospondins 1-3, osteonectin or osteopontin. Western blotting confirmed these changes 
at the protein level. In contrast, tumor necrosis factor  (TNF) did not modulate CCN2 
expression and had only a modest stimulatory effect on TNC levels. Signaling pathway 
inhibitor studies suggested an important role for the p38 MAPK pathway in suppressing 
CCN2 expression in response to IL-1. In contrast, multiple signaling pathways (p38, JNK, 
PI3K/Akt and NFB) contributed to IL-1-induced TNC expression. In conclusion, IL-1 
reduced CCN2 expression and increased TNC expression in human CF. These observations 
are of potential value for understanding how inflammation and ECM regulation are linked at 
the level of the CF.    
 
 
Key words: cardiac fibroblasts; interleukin-1; connective tissue growth factor; tenascin-C; 
signal transduction   
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1. Introduction 
The acute inflammatory response observed following myocardial infarction (MI)
1
 plays an 
integral role in tissue repair and the heart’s adaptation to injury (Nian et al., 2004; 
Frangogiannis et al., 2002). However, inflammatory mediators can also be detrimental and 
promote adverse cardiac remodeling and heart failure progression (Nian et al., 2004). The 
pro-inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor  (TNF) are two 
key players in the myocardial inflammatory response to injury. The inflammatory cells that 
infiltrate the infarct zone are the predominant source of these cytokines in the early stages 
following MI, however in the longer-term pro-inflammatory cytokines may be produced by 
myocardial cells at sites remote from the initial injury (Irwin et al., 1999; Deten et al., 2002). 
In addition to hematopoietic cells, cardiomyocytes and fibroblasts (the two major resident 
cell types of the heart) have the capacity to secrete TNF, and fibroblasts appear to be the 
main source of IL-1 (Jugdutt, 2003; Long, 2001). In turn these cytokines can have profound 
effects on the pathophysiology of cardiac myocytes and fibroblasts. Cardiomyocytes undergo 
apoptosis and/or hypertrophy in response to many pro-inflammatory cytokines, whilst 
fibroblasts adopt a myofibroblast phenotype and undergo increased proliferation and collagen 
turnover and thereby contribute to adverse post-MI remodeling (Porter and Turner, 2009; 
Jugdutt, 2003). IL-1 and TNF have each been shown to induce distinct patterns of 
extracellular matrix (ECM) protein and/or protease expression in the heart that contribute to 
adverse remodeling in heart failure (Bradham et al., 2002; Turner et al., 2010; Turner and 
Porter, 2012). 
 The matricellular proteins are a group of ECM proteins that are synthesized by a number 
of different cell types including fibroblasts, macrophages and endothelial cells 
                                                 
1
 Abbreviations: CF, cardiac fibroblast; CCN2/CTGF, connective tissue growth factor; ECM, extracellular 
matrix; HK, housekeeping gene; IL-1, interleukin-1; MI, myocardial infarction; TGF, transforming growth 
factor beta; TNC, tenascin-C; TNF, tumor necrosis factor. 
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(Frangogiannis, 2012). However, unlike structural matrix proteins, they do not play a 
principal role in tissue architecture, but serve as biological mediators of cell function by 
interacting with cells directly or by modulating the activity of cytokines, growth factors, 
proteases and other ECM proteins (Frangogiannis, 2012). Matricellular proteins can regulate 
cell movement, proliferation and differentiation during morphogenesis and the inflammatory 
and reparative response following tissue injury. The expanding family of matricellular 
proteins includes the thrombospondins (THBS 1-5), the CCN family (most notably CCN2; 
also known as connective tissue growth factor, CTGF), osteonectin (SPARC), osteopontin 
(SPP1), tenascin-C (TNC), tenascin-X, periostin and galectin (Frangogiannis, 2012).  
 Most matricellular proteins show increased expression in the heart following MI or stress 
where they act as transducers of key molecular signals in cardiac repair and as modulators of 
cell migration, proliferation and adhesion (Frangogiannis, 2012). Hence they play a vital 
function in tissue repair and post-MI remodeling. There is however, increasing evidence to 
suggest that the matricellular proteins may also modulate the inflammatory and fibrotic 
process in myocardial remodeling, which leads to cardiac dysfunction and heart failure 
(Dobaczewski et al., 2010; Okamoto and Imanaka-Yoshida, 2012; Schellings et al., 2004). 
 The aims of the present study were to determine whether IL-1 and TNF could modulate 
expression of matricellular proteins in human cardiac fibroblasts (CF) and to identify the 
intracellular signaling pathways responsible for these effects.  
 
2. Results 
2.1. Myofibroblast phenotype 
Human CF spontaneously adopted a myofibroblast phenotype when cultured in vitro, as 
defined by co-expression of -smooth muscle actin and vimentin (data not shown), in 
agreement with our previous reports (Porter et al., 2004b; Turner et al., 2003; Mughal et al., 
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2009). Such a phenotypic transition bears similarities to that observed when CF differentiate 
to myofibroblasts in vivo (Santiago et al., 2010) and so our findings with cultured human CF 
are particularly relevant to myofibroblast function in the remodeling heart.  
  
2.2. Effect of IL-1 on mRNA expression of matricellular proteins in human CF 
CF were stimulated with 10 ng/ml IL-1 for 6 h before extracting RNA and measuring 
mRNA levels of seven matricellular proteins as part of a focused RT-PCR array (Table 1). 
Although the array did not include all the known members of the matricellular protein family, 
it did facilitate evaluation of the most well-studied members. Unstimulated cells expressed 
particularly high basal mRNA levels of THBS1, SPARC (osteonectin) and CTGF/CCN2, and 
appreciable levels of THBS2. Basal TNC and THBS3 mRNA levels were relatively low, and 
SPP1 (osteopontin) levels were below the threshold of detection. IL-1 treatment had 
opposing effects on CCN2 and TNC expression; it decreased CCN2 expression by 80% and 
increased TNC expression by almost 10-fold (Table 1). mRNA expression levels of the other 
matricellular proteins were not markedly altered in response to IL-1 treatment (Table 1). 
 
2.3. Opposing effects of IL-1 on CCN2 and TNC expression 
Additional experiments were performed to confirm the array results for CCN2 and TNC. CF 
from 3 different patients were stimulated with IL-1, RNA extracted over a 2-24 h time 
course, and CCN2 and TNC mRNA levels determined by real-time RT-PCR with Taqman 
primer/probes sets. In agreement with the 6 h array data, IL-1 potently reduced CCN2 
mRNA levels, and this reduction of up to 80% was maintained over the full 2-24 h time 
course (Fig. 1A). TNC mRNA levels were increased over the same time period, with peak 
expression (10-fold increase) observed 4 h after IL-1 treatment, and levels remaining 
elevated by 7-fold even 24 h after IL-1 stimulation (Fig. 1B).  
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 Western blotting studies confirmed robust basal expression of CCN2 protein by human 
CF that was rapidly suppressed by IL-1 (Fig. 1C). CCN2 protein levels were decreased by 
80% within 4 h of IL-1 treatment, and remained low for at least 24 h (Fig. 1C). CCN2 
resolved as a doublet of 35-40 kDa, in agreement with previous studies (Abraham et al., 
2000). Western blotting also revealed that IL-1 stimulated protein expression of TNC, 
which was elevated 3.2-fold within 6 h and continued to rise to a 10-fold induction by 24 h 
(Fig. 1D). TNC resolved as a doublet of >250 kDa, in agreement with previous studies 
(Nakoshi et al., 2008). 
 
2.4. Comparison of effects of IL-1 and TNF 
We have previously shown that TNF is another important proinflammatory cytokine that 
can induce human CF migration, proliferation and altered gene expression (Porter et al., 
2004a; Turner et al., 2007; Turner et al., 2011). We therefore compared the effects of TNF 
(10 ng/ml, 6 h) with those of IL-1 (10 ng/ml, 6 h) on CCN2 and TNC mRNA and protein 
expression in a side-by-side manner. In stark contrast to the 70-80% inhibition in CCN2 
mRNA and protein observed with IL-1, TNF treatment had no significant effect on CCN2 
mRNA (Fig. 2A) or protein (Fig. 2C) levels. In contrast, TNF increased TNC mRNA levels 
by 2.6-fold (Fig. 2B), and appeared to induce TNC protein expression slightly (Fig. 2D), 
although this was not statistically significant and was much less than the response to IL-1.  
 
2.5. Signaling pathways mediating the effects of IL-1 on CCN2 and TNC expression 
IL-1 rapidly stimulates several intracellular signaling pathways in human CF, including 
ERK, p38 MAPK, JNK, PI3K/Akt and NFB (Turner et al., 2009). To determine which of 
these pathways were responsible for directly mediating the effects of IL-1 on CCN2 and 
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TNC expression, we pretreated cells with selective pharmacological inhibitors (PD98059, 
SB203580, SP600125, LY294002 and IMD-0354 respectively) before stimulating cells with 
IL-1 and measuring mRNA levels after 2 h or protein levels after 6 h (Fig. 3 and 4). These 
relatively early time points were selected to evaluate direct roles of the signaling pathways on 
gene expression, rather than any contribution via autocrine/paracrine signaling mechanisms. 
Inhibitors were used at concentrations that we have previously shown to effectively and 
selectively inhibit relevant pathways in this cell type (Turner et al., 2007).  
 The IL-1-mediated decrease in CCN2 expression at both mRNA (Fig. 3A) and protein 
(Fig. 3B) levels was attenuated by the p38 MAPK inhibitor SB203580, suggesting an 
important role for p38 MAPK in mediating the inhibitory effects of IL-1. None of the other 
inhibitors specifically affected the ability of IL-1 to reduce CCN2 mRNA expression, 
although SP600125, LY294002 and IMD-0354 did increase basal CCN2 mRNA levels (Fig. 
3A). The NFB pathway inhibitor IMD-0354 overcame the suppressive effect of IL-1 on 
CCN2 expression at the protein level, resulting in elevated CCN2 levels relative to control 
cells (Fig. 3B). However, this may have been due to an effect on basal expression, as IMD-
0354 alone induced a doubling of CCN2 mRNA levels in the absence of IL-1 (Fig. 3A). 
 The IL-1-induced increase in TNC mRNA expression was partially attenuated by 
inhibitors of p38 MAPK, JNK, PI3K/Akt and NFB pathways, but not the ERK pathway 
inhibitor PD98059 (Fig. 4A). PD98059 was similarly ineffective in modulating IL-1-
induced TNC protein levels, whereas the other inhibitors partially reduced TNC protein 
levels, with the NFB pathway inhibitor IMD-0354 being most effective (60% inhibition) 
(Fig. 4B). 
  
3. Discussion 
The key finding of our study was that IL-1 simultaneously down-regulated CCN2 and up-
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regulated TNC expression in human CF, without affecting expression of several other 
matricellular proteins. The TNC response to IL-1 was reproducibly higher than that induced 
by TNF, whereas TNF had no significant effect on CCN2 expression in these cells. 
Signaling inhibitor studies suggested an important role for the p38 MAPK pathway in IL-1-
mediated suppression of CCN2 levels, whereas a combination of several pathways (p38, 
JNK, PI3K/Akt and NFB) contributed to IL-1-induced TNC expression.  
 It is clear that the matricellular proteins play important roles in cardiac pathophysiology 
(Schellings et al., 2004; Frangogiannis, 2012). These molecules are minimally expressed in 
the healthy adult heart but are markedly upregulated in the injured and remodeling 
myocardium, where they regulate inflammatory, reparative, fibrotic and angiogenic 
processes. THBS1 is expressed in the early stages following MI and serves to limit the 
expansion of the inflammatory phase of infarct healing and so attenuates the spread of 
damage to the non-infarcted myocardium (Frangogiannis et al., 2005). In contrast, CCN2, 
TNC, SPARC and SPP1 are primarily expressed during the granulation and scar formation 
stages and are important for myofibroblast recruitment, collagen deposition and fiber 
assembly (Komatsubara et al., 2003; Tamaoki et al., 2005; Dobaczewski et al., 2006; 
Trueblood et al., 2001; Daniels et al., 2009; McCurdy et al., 2011). 
  In the present study, we were able to detect mRNA expression of THBS1-3, SPARC, 
CCN2 and TNC mRNA in human CMF, but SPP1 mRNA was not detectable. The high basal 
levels of expression of these matricellular proteins was likely due to the activated 
myofibroblast phenotype observed when human CF are grown in culture. Marked changes in 
mRNA expression were observed for CCN2 (decrease) and TNC (increase) following 
stimulation with IL-1 and the importance of these findings is discussed below. 
 
3.1. CCN2 
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CCN2 levels are elevated in various fibrotic disorders and it is reported to be an excellent 
surrogate marker for activated fibroblasts in wound healing and fibrosis (Daniels et al., 2009; 
Leask et al., 2009). CCN2 is strongly induced by transforming growth factor  (TGF) in 
human dermal fibroblasts (Leask et al., 2003) and there is evidence to suggest that CCN2 is a 
cofactor required to enhance the fibrotic response to TGF (Kennedy et al., 2007; Shi-wen et 
al., 2006). More recently a direct profibrotic effect of CCN2 (through the transcriptional 
activation of the collagen I 2 gene) was demonstrated in murine lung fibroblasts (Ponticos 
et al., 2009), and the loss of CCN2 was shown to provide resistance to bleomycin-induced 
skin fibrosis (Liu et al., 2011). On the basis of these profibrotic effects, it could be predicted 
that a down regulation of CCN2 by IL-1 may act to suppress profibrotic mechanisms during 
the inflammatory phase of post-MI remodeling (van Nieuwenhoven and Turner, 2013). 
 A recent transgenic study using cardiac-restricted overexpression of CCN2 demonstrated 
that rather than restricting cardiac function, as might be expected, CCN2 was found to elicit a 
number of cardioprotective effects, notably the induction of myocardial genes known to be 
involved in the regulation of cardiac growth and cardioprotection (Ahmed et al., 2011; 
Gravning et al., 2012). Moreover, mice with this transgene displayed remarkable resistance to 
dilated cardiomyopathy and heart failure and were protected against ischemia/reperfusion 
injury (Ahmed et al., 2011; Gravning et al., 2012). 
 Previous studies in fibroblasts of non-cardiac origin have determined that CCN2 
expression can be stimulated by profibrotic molecules such as TGFβ or angiotensin II, and 
inhibited by proinflammatory molecules such as IL-1 or TNF. For example, TGFβ-induced 
CCN2 expression was inhibited by TNF (Abraham et al., 2000; Beddy et al., 2006; Lin et 
al., 1998) or IL-1 (Nowinski et al., 2002; Nowinski et al., 2010) in human dermal 
fibroblasts or fibroblasts from bowel biopsies. In human dermal fibroblasts, IL-1 reduced 
TGFβ-induced CCN2 transcription via inhibitory effects on Smad3 (Nowinski et al., 2010), 
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whereas in mouse embryonic fibroblasts stimulated with TNF a role for Smad4 was 
proposed (Yu et al., 2009). Although we observed a consistent reduction in CCN2 expression 
following IL-1 treatment in human CF, no reduction was observed with TNF. We have 
previously reported that TNF responses in human CF are variable between cells from 
different patients (Porter et al., 2004a). However this observation is unlikely to explain the 
lack of effect on CCN2 expression, as TNC mRNA levels were elevated by TNF treatment 
in identical samples. Other groups have also reported that TNF does not inhibit basal CCN2 
expression in fibroblasts from non-cardiac sources, but can inhibit the TGFβ-induced 
increment in CCN2 expression (Abraham et al., 2000; Beddy et al., 2006; Yu et al., 2009). 
 CCN2 gene transcription is known to be positively or negatively influenced by a range of 
stimuli in different cell types (Daniels et al., 2009; Leask et al., 2009). Positive regulatory 
signals including TGF, angiotensin II, endothelin-1 and mechanical stretch can induce 
CCN2 gene expression through activation of Smads, protein kinase C, ERK and RhoA 
signaling pathways (Daniels et al., 2009; Leask et al., 2009). In contrast, inhibitors of CCN2 
gene transcription appear to act via the NFB, cyclic AMP, cyclic GMP and PPAR 
signaling pathways (Daniels et al., 2009; Leask et al., 2009). Our data revealed that IL-1 
strongly attenuated the high basal CCN2 expression in human CF at both mRNA and protein 
levels, and that this could be overcome by selective inhibition of the p38 MAPK pathway. 
The p38 MAPK pathway is an important signaling axis regulating CF function and represents 
an attractive therapeutic target for ameliorating cardiac dysfunction post-MI (Turner, 2011). 
Given that SB203580 inhibits the  and  subtypes of p38, but not p38- or - (Clark et al., 
2007), and our previously observation that human CF express the ,  and  subtypes of p38, 
but not p38- (Sinfield et al., 2013), our data most likely indicate a role for p38- in the IL-
1-mediated inhibition of CCN2 expression in this cell type. 
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3.2. TNC 
TNC plays an active role in the early stages of tissue repair (Chiquet-Ehrismann and Chiquet, 
2003; Imanaka-Yoshida et al., 2001; Tamaoki et al., 2005). Following MI, TNC can promote 
myocardial repair and prevent ventricular dilation by recruiting myofibroblasts to the site of 
injury and enhancing collagen fiber contraction (Tamaoki et al., 2005; Toma et al., 2005). On 
the other hand, TNC may also promote adverse myocardial remodeling. TNC has been shown 
to up-regulate MMP-2 and MMP-9 expression in a number of cell types (Kalembeyi et al., 
2003; Nishiura et al., 2005), enhance inflammatory responses through activation of NFB 
and cytokine upregulation (El-Karef et al., 2007; Midwood et al., 2009; Nakahara et al., 
2006), and inhibit the strong linkages that occur between cardiomyocytes and connective 
tissues (Imanaka-Yoshida et al., 2001; Imanaka-Yoshida et al., 2004). Although these 
functions are useful for clearing damaged tissue and releasing residual cardiomyocytes from 
connective tissue for rearrangement, they may also contribute to progressive degradation of 
ECM and slippage of myocytes within the myocardial wall, ultimately resulting in left 
ventricle wall thinning and dilation. Consistent with this, high serum levels of TNC in 
patients following MI have been associated with a greater incidence of adverse cardiac 
remodeling and poor prognosis, supporting the view that excessive and sustained increments 
of TNC could lead to detrimental myocardial remodeling (Sato et al., 2006). 
 Our data revealed that IL-1 strongly induced TNC expression in human CF, and that this 
could be partially reduced by inhibitors of the p38, JNK, PI3K/Akt and NFB pathways, with 
the NFB inhibitor being most potent. A recent study investigating the effects of IL-1β on 
TNC expression in synovial fibroblasts reported an upregulation of TNC expression, but only 
under hypoxic conditions (Tojyo et al., 2008). Although little is known regarding the 
mechanisms underlying transcription of the human TNC gene, there is accumulating evidence 
that the NFB pathway is pivotal (Nakoshi et al., 2008; Goh et al., 2010). In a study on 
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cultured human chondrocytes, NFB inhibition was found to prevent TNF-induced TNC 
mRNA and protein expression (Nakoshi et al., 2008). Moreover, in human monocyte-derived 
dendritic cells, lipopolysaccharide was shown to induce TNC expression via activation of the 
NFB and PI3K/Akt pathways, but not the p38, JNK or ERK pathways (Goh et al., 2010). 
The authors identified numerous putative NFB-binding sites within the promoter and first 
intron of the human TNC gene promoter that potentially mediate the stimulatory effect of 
lipopolysaccharide and other proinflammatory molecules (Goh et al., 2010). The induction of 
TNC in neonatal rat cardiac myocytes subjected to mechanical deformation also involved the 
activation of NFB, but occurred independently of PKC and MAPK activation (Yamamoto et 
al., 1999). Our data provide the first insight into regulation of TNC expression in human CF, 
and support a key role for NFB and PI3K/Akt pathways as well as the stress-activated 
kinases p38 and JNK. 
 
3.3. Conclusion 
We have demonstrated that the proinflammatory cytokine IL-1 has opposing effects on 
expression of CCN2 and TNC in human CF, whilst TNF has little or no effect. IL-1-
mediated inhibition of CCN2 expression occurred via a p38-dependent pathway and may act 
to suppress profibrotic mechanisms during the inflammatory phase of post-MI remodeling. 
Moreover, IL-1-induced upregulation of TNC may aid myofibroblast recruitment and drive 
early myocardial repair mechanisms following MI.      
 
4. Experimental Procedures 
4.1. Reagents 
Recombinant human IL-1 and TNF were purchased from Invitrogen. IMD-0354, 
PD98059, SB203580 and SP600125 were purchased from Calbiochem (Nottingham, UK) 
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and LY294002 was from Alexis Biochemicals (Nottingham, UK). 
  
4.2. Cell culture 
Right atrial appendage biopsies from multiple patients undergoing elective coronary artery 
bypass surgery at the Leeds General Infirmary were obtained following local ethical 
committee approval and informed patient consent. Primary cultures of CF were harvested, 
cultured and characterized as >99% pure population of -smooth muscle actin and vimentin 
co-expressing cells (i.e. myofibroblasts), as we have described previously (Porter et al., 
2004b; Turner et al., 2003; Mughal et al., 2009). Experiments were performed on early 
passage cells (P3-P5) from several different patients (indicated by n number). Cells were 
cultured under serum-free conditions for 48 h before performing experiments in medium 
supplemented with 0.4% fetal calf serum. 
 
4.3. RT-PCR Array 
Cells from 3 different patients were treated with or without 10 ng/ml IL-1 for 6 h before 
extracting RNA using the Aurum Total RNA kit (BioRad). Equivalent RNA samples from 
each of the 3 patients were pooled before preparing cDNA and measuring expression levels 
of matricellular proteins as part of a SYBR Green-based real-time PCR array (RT
2
 Profiler 
Human Extracellular Matrix and Adhesion Molecules, SABiosciences, Qiagen), as we 
described previously (Turner et al., 2010; Turner et al., 2011). ∆CT values for the target genes 
were calculated by subtracting the mean CT value (threshold cycle number) of the 5 
housekeeping (HK) genes on the array (β2-microglobulin, hypoxanthine 
phosphoribosyltransferase 1, ribosomal protein L13A,β-actin and glyceraldehyde-3-
phosphate dehydrogenase [GAPDH]) from the CT value of the target genes. Data are 
expressed as a percentage of the mean of HK genes using the formula 2
-∆CT x100. 
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4.4. Real-time RT-PCR 
RNA was extracted from cells (Aurum Total RNA kit) following appropriate treatments. 
Real-time RT-PCR was performed using intron-spanning human CCN2/CTGF 
(Hs00170014_m1) and TNC (Hs01115665_m1) primers and Taqman probes (Applied 
Biosystems). Data are expressed as percentage of GAPDH endogenous control mRNA 
expression (Hs99999905_m1 primers) using the formula 2
-∆CT x 100.  
 
4.5. Western Blotting 
Protein homogenates were prepared by directly scraping cell layers into sample buffer, and 
equal amounts of protein (typically 30 µg/lane) were resolved by SDS-PAGE before 
immunoblotting as described previously (Turner et al., 2001). Western blotting was 
performed using 1:1000 diluted goat polyclonal anti-CCN2 antibody (sc-14939, Santa Cruz 
Biotechnology) or 1:1000 diluted rabbit polyclonal anti-human TNC antibody (sc-20932, 
Santa Cruz Biotechnology), and immunolabelled proteins detected and densitometry 
quantified as described previously (Turner et al., 2001). Equal protein loading was confirmed 
with 1:7500 diluted mouse anti--actin monoclonal antibody (ab8226, Abcam). 
 
4.6. Statistical analysis 
Results are mean ± SEM with n representing the number of experiments on cells from 
different patients. Data were analyzed as ratios using repeated measures one-way ANOVA 
and Newman-Keuls post hoc test (GraphPad Prism software, www.graphpad.com), with 
P<0.05 considered statistically significant. 
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Figure Legends 
Fig. 1. Time course of effect of IL-1 on CCN2 and TNC expression. CF from 3 different 
patients were exposed to 10 ng/ml IL-1 for 2-24 h before measuring mRNA levels by RT-
PCR with primers for CCN2 (A) or TNC (B). Data are expressed as percentage GAPDH 
mRNA levels. ***P<0.001, **P<0.01 for effect of IL-1 (n=3). CF from a further 3 patients 
were exposed to 10 ng/ml IL-1 for 2-24 h before measuring protein levels of CCN2 (C) or 
TNC (D) by Western blotting. Approximate positions of molecular weight markers (kDa) are 
shown. Pooled densitometry data (mean ± SEM) are expressed relative to control. 
***P<0.001, **P<0.01, *P<0.05 vs. control for pooled densitometry data (n=3).  
 
Fig. 2. Comparison of effects of IL-1 and TNF on CCN2 and TNC expression. CF 
from 4 different patients were exposed to 10 ng/ml IL-1 or 10 ng/ml TNF for 6 h before 
measuring mRNA levels by RT-PCR with primers for CCN2 (A) or TNC (B). Data are 
expressed as percentage GAPDH mRNA levels. ***P<0.001, **P<0.01, NS = not significant 
vs. control (n=4). CF from a further 3 patients were exposed to 10 ng/ml IL-1 or 10 ng/ml 
TNF for 6 h before measuring protein levels of CCN2 (C) or TNC (D) by Western blotting. 
Approximate positions of molecular weight markers (kDa) are shown. Pooled densitometry 
data (mean ± SEM) are expressed relative to control. **P<0.01, *P<0.05, NS = not 
significant vs. control for pooled densitometry data (n=3).  
 
Fig. 3. Effect of signaling pathway inhibitors on IL-1-mediated suppression of CCN2 
mRNA and protein expression. CF from multiple patients were exposed to 30 M PD98059 
(PD; ERK pathway inhibitor), 10 M SB203580 (SB; p38 MAPK pathway inhibitor), 10 M 
SP600125 (SP; JNK pathway inhibitor), 10 M LY294002 (LY; PI3K/Akt pathway 
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inhibitor) or 10 M IMD-0354 (IMD; NFB pathway inhibitor) for 1 h before stimulation 
with or without 10 ng/ml IL-1 for a further 2 h (for mRNA studies) or 6 h (for protein 
studies). (A) CCN2 mRNA levels were measured by RT-PCR. Data are normalized to 
GAPDH mRNA levels. **P<0.01, *P<0.05, NS = not significant for effect of IL-1 (n=5). (B) 
CCN2 protein levels were measured by Western blotting. Approximate position of molecular 
weight marker (kDa) is shown. Pooled densitometry data for CCN2 (mean ± SEM) are 
expressed relative to control (n=4).  
 
Fig. 4. Effect of signaling pathway inhibitors on IL-1-induced TNC mRNA and protein 
expression. CF from multiple patients were exposed to 30 M PD98059 (PD; ERK pathway 
inhibitor), 10 M SB203580 (SB; p38 MAPK pathway inhibitor), 10 M SP600125 (SP; 
JNK pathway inhibitor), 10 M LY294002 (LY; PI3K/Akt pathway inhibitor) or 10 M 
IMD-0354 (IMD; NFB pathway inhibitor) for 1 h before stimulation with or without 10 
ng/ml IL-1 for a further 2 h (for mRNA studies) or 6 h (for protein studies). (A) TNC 
mRNA levels were measured by RT-PCR. Data are normalized to GAPDH mRNA levels. 
**P<0.01, *P<0.05, NS = not significant for effect of IL-1 (n=5). (B) TNC protein levels 
were measured by Western blotting. Approximate position of molecular weight marker (kDa) 
is shown. Pooled densitometry data for TNC (mean ± SEM) are expressed relative to control 
(n=4). 
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